About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

PRostate Cancer Enhanced Diagnosis by Calibration Technology

NCT06607783·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lucy Newton
CONTACT
0044 7745627050 lucy.newton@goldstandardphantoms.com

Lead

Gold Standard Phantoms

With

Bioxydyn Ltd, Manchester
National Cancer Imaging Translational Accelerator
University College London Hospitals
National Hospital for Neurology and Neurosurgery

Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Men aged 18 years and older undergoing investigations for PCa.
Standard of Care MRI conducted.
One or more lesions with a Likert score of 3 or above identified on clinical reports.
Planned targeted biopsy within 6 months from the date of clinical care MRI.
Willing and able to provide written informed consent.

You may not be if

Prostate specific antigen (PSA) level \> 20ng/ml within 6 months
Previous diagnosis of prostate cancer
Ongoing hormone treatment within 3 months prior to MRI, excluding antiandrogens or 5-alpha reductase inhibitors
Contraindication to MRI scan

The record

StatusRecruiting

PhaseNo phase

Taking part66

StartedJun 2026

UpdatedSep 9, 2026

Conditions

Prostate Cancers

Where1

University College Hospital
London, London, United Kingdom

Clareo Health | PRostate Cancer Enhanced Diagnosis by Calibration Technology